News | January 11, 2026
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
